Jump to main content
Jump to site search

Issue 28, 2017
Previous Article Next Article

Micellar nanoformulation of lipophilized bortezomib: high drug loading, improved tolerability and targeted treatment of triple negative breast cancer

Author affiliations

Abstract

Bortezomib (BTZ) is the first proteasome inhibitor approved for the treatment of malignant tumors. The current clinical formulation, however, shows fast clearance, low tumor accumulation, and several side effects. Here, we report that micellar nanoformulation of lipophilized bortezomib achieves significantly enhanced drug loading, prolonged circulation time, improved tolerability and targeted treatment of triple negative breast cancer in vivo. Lipophilized bortezomib, bortezomib-pinanediol (BP), was readily prepared in high yield. Interestingly, cRGD-targeted micelles based on poly(ethylene glycol)-b-poly(trimethylene carbonate-co-dithiolane trimethylene carbonate) achieved a high drug loading content of 8.05 wt% BTZ equiv. for BP, which was more than 8-fold higher than BTZ. BP-loaded cRGD-decorated micelles (BP-cRGD-Ms) exhibited a small size (ca. 49 nm), reduction-triggered drug release, and active targeting ability to αvβ3-overexpressing MDA-MB-231 triple-negative breast cancer cells, resulting in a low IC50 of 0.986 μM. The in vivo studies displayed that BP-cRGD-Ms had a nearly 20-fold improvement in the elimination half-life and a 20-fold higher maximum-tolerated dose as compared to free BTZ. The biodistribution and therapeutic studies in MDA-MB-231 tumor-bearing nude mice demonstrated that BP-cRGD-Ms induced significantly better tumor accumulation and inhibition with fewer adverse effects than free BTZ, leading to greatly improved mice survival rates. This micellar nanoformulation of lipophilized bortezomib appears to be a novel and effective strategy to achieve targeted tumor chemotherapy with bortezomib.

Graphical abstract: Micellar nanoformulation of lipophilized bortezomib: high drug loading, improved tolerability and targeted treatment of triple negative breast cancer

Back to tab navigation

Supplementary files

Publication details

The article was received on 12 May 2017, accepted on 14 Jun 2017 and first published on 14 Jun 2017


Article type: Paper
DOI: 10.1039/C7TB01297G
Citation: J. Mater. Chem. B, 2017,5, 5658-5667
  •   Request permissions

    Micellar nanoformulation of lipophilized bortezomib: high drug loading, improved tolerability and targeted treatment of triple negative breast cancer

    K. Wu, R. Cheng, J. Zhang, F. Meng, C. Deng and Z. Zhong, J. Mater. Chem. B, 2017, 5, 5658
    DOI: 10.1039/C7TB01297G

Search articles by author

Spotlight

Advertisements